# Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Source: https://onco.cc/trials/nct05471843/  
OnCo record `nct05471843` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Sonrotoclax in mantle cell lymphoma, run by BeiGene, active and no longer recruiting.

## Summary

Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma is a phase 1/2 interventional study registered as NCT05471843 by BeiGene, with 125 participants enrolled, started 2022-09-05 and due to reach its primary completion in 2025-07-18. Interventions recorded: BGB-11417. Conditions listed: Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT05471843
- Phase: 1/2
- Setting: A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Sponsor: BeiGene
- Enrolled: 125
- Outcomes: Part 2: Overall Response Rate (ORR) as Assessed by the Independent Review Committee (IRC): Part 2: Sonrotoclax 320 mg (Daily Ramp-up) 44.2% vs Part 2: Sonrotoclax 320 mg (Twice-weekly Ramp-up) 58.3% vs Part 2: Sonrotoclax 320 mg Total 52.4%; Part 1: Overall Survival (OS): Part 1: Sonrotoclax 160 mg (Daily Ramp-up) 11.4 months vs Part 1: Sonrotoclax 320 mg (Daily Ramp-up) 9.5 months

## Sources

- ClinicalTrials.gov NCT05471843: https://clinicaltrials.gov/study/NCT05471843

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- technologies: [BCL-2 inhibitors](https://onco.cc/technologies/bcl2-inhibitors/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Sonrotoclax](https://onco.cc/drugs/sonrotoclax/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct05471843.json